Table 4.
Results of the therapy with rituximab.
| CAS score (/7) | Vision | IPO (mmHg) | Proptosis (mm) | Diplopia | |||||
|---|---|---|---|---|---|---|---|---|---|
| Right | Left | Right | Left | Right | Left | Right | Left | ||
| Patient 1 | |||||||||
| Before RTX | 5 | 6 | 0.5 | 0.6 | 19 | 15 | 21 | 20 | Yes |
| 5 months after RTX | 2 | 3 | 1.0 | 0.8 | 18 | 14 | 20 | 21 | Alleviated |
| Last examination 24 months after RTX | 2 | 2 | 1.0 | 0.8 | 18 | 15 | 19 | 20 | Alleviated |
| Patient 2 | |||||||||
| Before RTX | 7 | 3 | 0.4 | 1.0 | 21 | 19 | 19 | 19 | Yes |
| 6 months after RTX | 2 | 0 | 0.8 | 1.0 | 19 | 17 | 18 | 18 | Alleviated |
| Last examination 26 months after RTX | 0 | 0 | 1.0 | 1.2 | 19 | 17 | 18 | 19 | No |
CAS, Clinical Activity Score; IPO, intraocular pressure; RTX, rituximab.